{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:25:23Z","timestamp":1787315123758,"version":"build-2736575974"},"reference-count":141,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Epithelioid sarcoma (EPS) is an ultra-rare malignant mesenchymal neoplasm of uncertain differentiation that comprises two distinct clinicopathological subtypes: classic and proximal. Classic EPS most commonly occurs in the distal upper extremity of adolescents and young adults, whereas proximal-type EPS most often affects the truncal regions of young to middle-aged adults. Both classic and proximal-type EPSs exhibit aggressive clinical behavior, including a higher risk of local recurrence and regional lymph node or distant metastasis. Histologically, classic EPS is characterized by irregular nodules composed of epithelioid and spindled cells, while proximal-type EPS consists of multinodular distributions and sheets of large polygonal cells. EPS has a distinctive immunoprofile with characteristic expression of cytokeratins and epithelial membrane antigen. Loss of nuclear expression of SMARCB1 protein occurs in the vast majority of cases. Moreover, SMARCB1 homozygous deletions have also been observed in both subtypes. Surgery is the mainstay treatment approach for localized EPS. Systemic treatment options for metastatic or unresectable locally advanced disease are very limited. The withdrawal of tazemetostat has created a significant gap in available treatment options. In this review, we provide an overview of the current knowledge on the clinical and radiological features, histopathology, immunohistochemistry, pathogenesis, and management of EPS.<\/jats:p>","DOI":"10.3390\/cancers18162717","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:37:34Z","timestamp":1787312254000},"page":"2717","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epithelioid Sarcoma: A Review and Update"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0188-8000","authenticated-orcid":false,"given":"Jun","family":"Nishio","sequence":"first","affiliation":[{"name":"Section of Orthopaedic Surgery, Department of Medicine, Fukuoka Dental College, 2-15-1 Tamura, Sawara-ku, Fukuoka 814-0193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9734-3496","authenticated-orcid":false,"given":"Shizuhide","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Nakayama Orthopaedic Clinic, 6-10-3 Umebayashi, Sawara-ku, Fukuoka 814-0172, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-1383","authenticated-orcid":false,"given":"Mikiko","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/1097-0142(197011)26:5<1029::AID-CNCR2820260510>3.0.CO;2-R","article-title":"Epithelioid sarcoma. A sarcoma simulating a granuloma or a carcinoma","volume":"26","author":"Enzinger","year":"1970","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s11999-009-0749-2","article-title":"Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database","volume":"467","author":"Jawad","year":"2009","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.ejso.2020.03.215","article-title":"The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group","volume":"46","author":"Frezza","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_4","unstructured":"Oda, Y., Dal Cin, P., Le Loarer, F., and Nielsen, T.O. (2020). Epithelioid sarcoma. World Health Organization (WHO) Classification of Soft Tissue and Bone Tumours, International Agency for Research on Cancer (IARC). [5th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/cncr.21630","article-title":"Epithelioid sarcoma in children and adolescents: A report from the Italian Soft Tissue Sarcoma Committee","volume":"106","author":"Casanova","year":"2006","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00000478-199702000-00002","article-title":"Proximal-type epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features: Clinicopathologic, immunohistochemical, and ultrastructural study of a series","volume":"21","author":"Guillou","year":"1997","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/modpathol.3880368","article-title":"Proximal-type epithelioid sarcoma: A clinicopathologic study of 20 cases","volume":"14","author":"Hasegawa","year":"2001","journal-title":"Mod. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.22037","article-title":"Epithelioid sarcoma: Still an only surgically curable disease","volume":"107","author":"Wobbes","year":"2006","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/1097-0142(197804)41:4<1472::AID-CNCR2820410436>3.0.CO;2-W","article-title":"Epithelioid sarcoma: An analysis of 22 cases indicating the prognostic significance of vascular invasion and regional lymph node metastasis","volume":"41","author":"Prat","year":"1978","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00000478-198504000-00001","article-title":"Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment","volume":"9","author":"Chase","year":"1985","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00432-009-0678-1","article-title":"Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma","volume":"136","author":"Hoshino","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jjco\/hyg030","article-title":"Epithelioid sarcomas with elevated serum CA125: Report of two cases","volume":"33","author":"Kato","year":"2003","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.5858\/2006-130-871-PESWES","article-title":"Proximal-type epithelioid sarcoma with elevated serum CA125","volume":"130","author":"Lee","year":"2006","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2500404","DOI":"10.1200\/PO-25-00404","article-title":"Mucin 16-derected therapy in pediatric sarcomas: Case evidence of ubamatamab efficacy in epithelioid sarcoma and its implications for other sarcoma subtypes","volume":"9","author":"Connolly","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jjco\/hyh027","article-title":"CA125 expression in epithelioid sarcoma","volume":"34","author":"Kato","year":"2004","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejca.2010.09.003","article-title":"Prognostic determinants in epithelioid sarcoma","volume":"47","author":"Gasparini","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/0284186X.2019.1659514","article-title":"Epithelioid sarcoma: Half a century later","volume":"59","author":"Elsamna","year":"2020","journal-title":"Acta Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/BF02523657","article-title":"Epithelioid sarcoma: The clinicopathological complexities of this rare soft tissue sarcoma","volume":"7","author":"Spillane","year":"2000","journal-title":"Ann. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1002\/cam4.5230","article-title":"Prognostic nomogram in patients with epithelioid sarcoma: A SEER-based study","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e29969","DOI":"10.1097\/MD.0000000000029969","article-title":"Clinical characteristics and survival analysis of patients with limb epithelioid sarcoma","volume":"101","author":"Lu","year":"2022","journal-title":"Medicine"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Czarnecka, A.M., Sobczuk, P., Kostrzanowski, M., Spalek, M., Chojnacka, M., Szumera-Cieckiewicz, A., and Rutkowski, P. (2020). Epithelioid sarcoma\u2014From genetics to clinical practice. Cancers, 12.","DOI":"10.3390\/cancers12082112"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2214\/ajr.179.4.1790973","article-title":"Radiologic manifestations of proximal-type epithelioid sarcoma of the soft tissues","volume":"179","author":"Tateishi","year":"2002","journal-title":"Am. J. Roentgenol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e12529","DOI":"10.1097\/MD.0000000000012529","article-title":"Epithelioid sarcoma arising from the temporal space: A case report","volume":"97","author":"Kim","year":"2018","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Yin, H., Zhang, Y., Wu, L., and Zhang, J. (2023). Imaging findings of primary epithelioid sarcoma of adrenal gland: A case report and literature review. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1015258"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00256-002-0509-9","article-title":"Epithelioid sarcoma: Clinical, MR imaging and pathologic findings","volume":"31","author":"Hanna","year":"2002","journal-title":"Skelet. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s00247-019-04389-2","article-title":"Magnetic resonance and computed tomography imaging features of epithelioid sarcoma in children and young adults with pathological and clinical correlation: A report from Children\u2019s Oncology Group Study ARST0332","volume":"49","author":"McCarville","year":"2019","journal-title":"Pediatr. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3892\/ol.2014.1876","article-title":"Role of FDG-PET\/CT for monitoring soft tissue tumors","volume":"7","author":"Hoshi","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kawasaki, T., Watanabe, T., Kanno, S., Torigoe, T., Onohara, K., Wako, M., Hagino, T., and Ichikawa, J. (2025). Proximal epithelioid sarcoma mimicking inguinal inflammation. Diagnostics, 15.","DOI":"10.3390\/diagnostics15172246"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/RLU.0b013e31824853db","article-title":"Proximal-type epithelioid sarcoma of the scrotum: 18F-FDG PET\/CT imaging","volume":"38","author":"Nguyen","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/RLU.0b013e318156b992","article-title":"FDG PET\/CT findings of epithelioid sarcoma in a pediatric patient","volume":"32","author":"Chen","year":"2007","journal-title":"Clin. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0046-8177(99)90247-2","article-title":"Epithelioid sarcoma: An immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis","volume":"30","author":"Miettinen","year":"1999","journal-title":"Hum. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1309\/AJCPU98ABIPVJAIV","article-title":"Epithelioid sarcoma: A clinicopathologic and immunohistochemical analysis of 106 cases from the French Sarcoma Group","volume":"131","author":"Chbani","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/modpathol.2013.161","article-title":"ERG and FLI1 protein expression in epithelioid sarcoma","volume":"27","author":"Stockman","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1097\/PAS.0b013e31828de23a","article-title":"ERG expression in epithelioid sarcoma: A diagnostic pitfall","volume":"37","author":"Miettinen","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/PAS.0b013e3181882c54","article-title":"Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma","volume":"33","author":"Hornick","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/modpathol.3800599","article-title":"Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor","volume":"19","author":"Izumi","year":"2006","journal-title":"Mod. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0560.1986.tb01520.x","article-title":"Epithelioid sarcoma and isolated necrobiotic granuloma: A comparative immunohistochemical study","volume":"13","author":"Wick","year":"1986","journal-title":"J. Cutan. Pathol."},{"key":"ref_38","first-page":"82","article-title":"Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens\u2014Evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor","volume":"7","author":"Miettinen","year":"1994","journal-title":"Mod. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.humpath.2012.06.014","article-title":"Glypican 3 expression in tumors with loss of SMARCB1\/INI1 protein expression","volume":"44","author":"Kohashi","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.humpath.2014.10.010","article-title":"ERG and SALL4 expressions in SMARCB1\/INI1-deficient tumors: A useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor","volume":"46","author":"Kohashi","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00000478-200301000-00006","article-title":"Epithelioid sarcoma-like hemangioendothelioma","volume":"27","author":"Billings","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cancergen.2011.01.002","article-title":"Translocation t(7;19)(q22;q13)\u2014A recurrent chromosome aberration in pseudomyogenic hemangioendothelioma","volume":"204","author":"Trombetta","year":"2011","journal-title":"Cancer Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/path.4322","article-title":"A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic hemangioendothelioma","volume":"232","author":"Walther","year":"2014","journal-title":"J. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/PAS.0000000000000795","article-title":"FOSB is a useful diagnostic marker for pseudomyogenic hemangioendothelioma","volume":"41","author":"Hung","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_45","unstructured":"Suuemeijer, A.J.H., Ladanyi, M., and Nielsen, T.O. (2020). Synovial sarcoma. World Health Organization (WHO) Classification of Soft Tissue and Bone Tumours, International Agency for Research on Cancer (IARC). [5th ed.]."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/gcc.22159","article-title":"Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material","volume":"53","author":"Zhang","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/1097-0142(19900501)65:9<2006::AID-CNCR2820650921>3.0.CO;2-Q","article-title":"A cell culture, chromosomal and quantitative DNA analysis of a metastatic epithelioid sarcoma. Deletion 1p, a possible primary chromosomal abnormality in epithelioid sarcoma","volume":"65","author":"Stenman","year":"1990","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0165-4608(94)90132-5","article-title":"A new cytogenetic finding in an epithelioid sarcoma, t(8;22)(q22;q11)","volume":"72","author":"Cordoba","year":"1994","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0165-4608(95)00315-0","article-title":"Epithelioid sarcoma with an 18q aberration","volume":"91","author":"Iwasaki","year":"1996","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_50","first-page":"178","article-title":"Involvement of 8q, 22q, and monosomy 21 in an epithelioid sarcoma","volume":"96","author":"Sonobe","year":"1997","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_51","first-page":"80","article-title":"Epithelioid sarcoma of the proximal type with complex karyotype including i(8q)","volume":"114","author":"Pauwels","year":"1999","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1096-911X(199908)33:2<137::AID-MPO18>3.0.CO;2-N","article-title":"Brief report: Neural differentiation of a novel cell line, YCUC-5, established from proximal-type epithelioid sarcoma of a child","volume":"33","author":"Goto","year":"1999","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0165-4608(99)00218-6","article-title":"Cytogenetic findings in a case of epithelioid sarcoma and a review of the literature","volume":"119","author":"Feely","year":"2000","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0165-4608(00)00320-4","article-title":"Common chromosome aberrations in the proximal type of epithelioid sarcoma","volume":"123","author":"Sciot","year":"2000","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_55","first-page":"361","article-title":"Establishment of a new human epithelioid sarcoma cell line, FU-EPS-1: Molecular cytogenetic characterization by use of spectral karyotyping and comparative genomic hybridization","volume":"27","author":"Nishio","year":"2005","journal-title":"Int. J. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/gcc.20086","article-title":"Molecular cytogenetic characterization of proximal-type epithelioid sarcoma","volume":"41","author":"Lualdi","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0046-8177(98)80010-5","article-title":"Allelic loss on chromosome 22q in epithelioid sarcoma","volume":"29","author":"Quezado","year":"1998","journal-title":"Hum. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/modpathol.3880203","article-title":"DNA copy number changes in epithelioid sarcoma and its variants: A comparative genomic hybridization study","volume":"13","author":"Lushnikova","year":"2000","journal-title":"Mod. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1365-2133.2004.06246.x","article-title":"Comparative genomic hybridization in epithelioid sarcoma","volume":"151","author":"Lee","year":"2004","journal-title":"Br. J. Derm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/modpathol.3800349","article-title":"Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma","volume":"18","author":"Lin","year":"2005","journal-title":"Mod. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/modpathol.2012.175","article-title":"Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions","volume":"26","author":"Sullivan","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1158\/0008-5472.CAN-04-3050","article-title":"SMARCB1\/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas","volume":"65","author":"Modena","year":"2005","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/path.4636","article-title":"The genomic landscape of epithelioid sarcoma cell lines and tumours","volume":"238","author":"Jamshidi","year":"2016","journal-title":"J. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41379-022-01148-x","article-title":"The genetic landscape of SMARCB1 alterations in SMARCB1-deficient spectrum of mesenchymal neoplasms","volume":"35","author":"Dermawan","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Del Savio, E., and Maestro, R. (2022). Beyond SMARCB1 loss: Recent insights into the pathobiology of epithelioid sarcoma. Cells, 11.","DOI":"10.3390\/cells11172626"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cas.13173","article-title":"Oncogenic roles of SMARCB1\/INI1 and its deficient tumors","volume":"108","author":"Kohashi","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/1078-0432.CCR-13-0280","article-title":"Molecular pathways: SW1\/SNF (BAF) complexes are frequently mutated in cancer\u2014Mechanisms and potential therapeutic insights","volume":"20","author":"Wang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_68","unstructured":"Oda, Y., Biegel, J.A., and Pfister, S.M. (2020). Extrarenal rhabdoid tumour. World Health Organization (WHO) Classification of Soft Tissue and Bone Tumours, International Agency for Research on Cancer (IARC). [5th ed.]."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.humpath.2014.06.027","article-title":"Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: Implications for the cocontributions of multiple SWI\/SNF complex members to pathogenesis","volume":"45","author":"Li","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/PAS.0000000000001011","article-title":"SWI\/SNF chromatin-remodeling complex status in SMARCB1\/INI1-preserved epithelioid sarcoma","volume":"42","author":"Kohashi","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_71","first-page":"1","article-title":"SMARCA4-deficient epithelioid sarcoma revealed by comprehensive genomic profiling, leading to a notable response by nivolumab treatment","volume":"14","author":"Tokunaga","year":"2025","journal-title":"Int. Cancer Conf. J."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Correia de Sousa, M., Gjorgjieva, M., Dolicka, D., Sobolewski, C., and Foti, M. (2019). Deciphering miRNAs\u2019 action through miRNA editing. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246249"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/modpathol.2013.213","article-title":"Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: MiR193a-5p is suggested to downregulate SMARCB1 mRNA expression","volume":"27","author":"Kohashi","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/gcc.22128","article-title":"SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on both mRNA and protein levels","volume":"53","author":"Papp","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/gcc.22379","article-title":"Epigenetic regulation of SMARCB1 by miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas","volume":"55","author":"Papp","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-11-0660","article-title":"Combining EGFR and MTOR blockade for the treatment of epithelioid sarcoma","volume":"17","author":"Xie","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1476-4598-13-185","article-title":"Combined targeting of MTOR and C-MET signaling pathways for effective management of epithelioid sarcoma","volume":"13","author":"Imura","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/modpathol.2010.2","article-title":"Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare","volume":"23","author":"Cascio","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/COC.0b013e31823a4970","article-title":"Phase II trial of cetuximab in patients with metastatic or local advanced soft tissue or bone sarcoma","volume":"36","author":"Ha","year":"2013","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s004280050175","article-title":"Expression of c-Met receptor and hepatocyte growth factor\/scatter factor in synovial sarcoma and epithelioid sarcoma","volume":"432","author":"Kuhnen","year":"1998","journal-title":"Virchows Arch."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13569-019-0122-5","article-title":"A clinic-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis","volume":"9","author":"Bui","year":"2019","journal-title":"Clin. Sarcoma Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4172\/jpb.1000316","article-title":"Proteomic profile of epithelioid sarcoma","volume":"7","author":"Mukaihara","year":"2014","journal-title":"J. Proteom. Bioinform."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Mukaihara, K., Suehara, Y., Kohsaka, S., Kubota, D., Toda-Ishii, M., Akaike, K., Fujimura, T., Kobayashi, E., Yao, T., and Ladanyi, M. (2016). Expression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2235-z"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s004320050036","article-title":"Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours","volume":"126","author":"Kuhnen","year":"2000","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1634\/theoncologist.2010-0174","article-title":"Epithelioid sarcoma and unclassified sarcoma with epithelioid features: Clinicopathological variables, molecular markers, and a new experimental model","volume":"16","author":"Sakharpe","year":"2011","journal-title":"Oncologist"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00441-003-0748-7","article-title":"Lymphangiogenesis and tumor metastasis","volume":"314","author":"Pepper","year":"2003","journal-title":"Cell Tissue Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccr.2006.02.018","article-title":"The VEGF-C\/Flt-4 axis promotes invasion and metastasis of cancer cells","volume":"9","author":"Su","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1158\/1078-0432.CCR-08-2442","article-title":"Increased vascular endothelial growth factor-C expression is insufficient to induce lymphatic metastasis in human soft-tissue sarcomas","volume":"15","author":"Lahat","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"102093","DOI":"10.1016\/j.labinv.2024.102093","article-title":"Expression of forkhead box M1 and anticancer effects of FOXM1 inhibition in epithelioid sarcoma","volume":"104","author":"Shibui","year":"2024","journal-title":"Lab. Invest."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"42792","DOI":"10.18632\/oncotarget.8669","article-title":"FOXM1 in sarcoma: Role in cell cycle, pluripotency genes and stem cell pathways","volume":"7","author":"Kelleher","year":"2016","journal-title":"Oncotarget"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.modpat.2024.100647","article-title":"Proximal and classic epithelioid sarcomas are distinct molecular entities defined by MYC\/GATA3 and SOX17\/endothelial markers, respectively","volume":"38","author":"Sigalotti","year":"2025","journal-title":"Mod. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e961","DOI":"10.1002\/ctm2.961","article-title":"Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology","volume":"12","author":"Rasmussen","year":"2022","journal-title":"Clin. Trans. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1245\/s10434-023-13142-x","article-title":"Practice pattern variability in the management of regional lymph node metastasis in extremity and trunk soft tissue sarcoma: A survey of the society of surgical oncology and musculoskeletal tumor society membership","volume":"30","author":"Witt","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/curroncol31010020","article-title":"Review on lymph node metastases, sentinel lymph node biopsy, and lymphadenectomy in sarcoma","volume":"31","author":"Chmiel","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0360-3016(01)01646-7","article-title":"Epithelioid sarcoma: Results of conservative surgery and radiotherapy","volume":"51","author":"Callister","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.amjsurg.2007.07.029","article-title":"Epithelioid sarcoma: The University of Washington experience","volume":"196","author":"Wolf","year":"2008","journal-title":"Am. J. Surg."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/1097-0142(19830915)52:6<1022::AID-CNCR2820520616>3.0.CO;2-I","article-title":"Radiation therapy of epithelioid sarcoma","volume":"52","author":"Shimm","year":"1983","journal-title":"Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"111846","DOI":"10.1016\/j.apradiso.2025.111846","article-title":"Potential of boron neutron capture therapy (BNCT) for epithelioid sarcoma","volume":"222","author":"Fujimoto","year":"2025","journal-title":"Appl. Radiat. Isot."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/cncr.33365","article-title":"Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma","volume":"127","author":"Gounder","year":"2021","journal-title":"Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41416-024-02674-y","article-title":"UK guidelines for the management of soft tissue sarcomas","volume":"132","author":"Hayes","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e180219","DOI":"10.1001\/jamaoncol.2018.0219","article-title":"Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: A multi-institutional case series","volume":"4","author":"Frezza","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.clon.2018.02.065","article-title":"European Organisation for research and treatment of cancer soft tissue and bone sarcoma group experience with advanced\/metastatic epithelioid sarcoma patients treated in prospective trials: Clinical profile and response to systemic therapy","volume":"30","author":"Touati","year":"2018","journal-title":"Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000362602","article-title":"Gemcitabine and docetaxel for epithelioid sarcoma: Results from a retrospective, multi-institutional analysis","volume":"87","author":"Pink","year":"2014","journal-title":"Oncology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"FSO822","DOI":"10.2144\/fsoa-2021-0138","article-title":"Epithelioid sarcoma and its outcome: A retrospective analysis from a tertiary care center in North India","volume":"8","author":"Kashyap","year":"2023","journal-title":"Future Sci. OA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1634\/theoncologist.12-8-999","article-title":"Gemcitabine and docetaxel in metastatic sarcoma: Past, present, and feature","volume":"12","author":"Maki","year":"2007","journal-title":"Oncologist"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2165\/00002512-199405030-00006","article-title":"Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy","volume":"5","author":"Goa","year":"1994","journal-title":"Drugs Aging"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"15947","DOI":"10.1155\/SRCM\/2006\/15947","article-title":"A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas","volume":"2006","author":"Anderson","year":"2006","journal-title":"Sarcoma"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1097\/MJT.0b013e3181e70a50","article-title":"A case report of complete remission of pulmonary metastases from epithelioid sarcoma to navelbine chemotherapy","volume":"19","author":"Tariq","year":"2012","journal-title":"Am. J. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Xie, L., Sun, X., Xu, J., Liang, X., Liu, K., Sun, K., Yang, R., Tang, X., and Guo, W. (2024). The efficacy and safety of vincristine, irinotecan and anlotinib in epithelioid sarcoma. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11921-7"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000439427","article-title":"Successful treatment with pazopanib for multiple lung metastases of inguinal epithelioid sarcoma: A case report","volume":"8","author":"Irimura","year":"2015","journal-title":"Case Rep. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1111\/cas.14542","article-title":"Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study","volume":"111","author":"Urakawa","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3332\/ecancer.2021.1281","article-title":"Pazopanib in rare histologies of metastatic soft tissue sarcoma","volume":"15","author":"Kataria","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bjd.12038","article-title":"Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate","volume":"168","author":"Penot","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.30379","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor","volume":"123","author":"Schuetze","year":"2017","journal-title":"Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Nakamura, T., and Sudo, A. (2022). The role of trabectedin in soft tissue sarcoma. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.777872"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejca.2015.01.006","article-title":"Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group","volume":"51","author":"Duffaud","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: An international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"11549","DOI":"10.1200\/JCO.2024.42.16_suppl.11549","article-title":"Efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase 2 trial","volume":"42","author":"Zhou","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"103398","DOI":"10.1016\/j.eclinm.2025.103398","article-title":"Safety and efficacy of HH2853, a novel EZH1\/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: A phase I study","volume":"86","author":"Fan","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ngo, C., and Postel-Vinay, S. (2022). Immunotherapy for SMARCB1-deficient sarcomas: Current evidence and future developments. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030650"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Kim, C., Kim, E.K., Jung, H., Chon, H.J., Han, J.W., Shin, K.H., Hu, H., Kim, K.S., Choi, Y.D., and Kim, S. (2016). Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2451-6"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1158\/1078-0432.CCR-19-3089","article-title":"Genomic and immunologic characterization of INI1-deficient pediatric cancers","volume":"26","author":"Forrest","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/path.6135","article-title":"Subclassification of epithelioid sarcoma with potential therapeutic impact","volume":"260","author":"Haefliger","year":"2023","journal-title":"J. Pathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/cac2.70077","article-title":"Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics","volume":"45","author":"Ngo","year":"2025","journal-title":"Cancer Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): Interim analysis of an open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): Analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3892\/etm.2022.11595","article-title":"Response to immunotherapy in a patient with advanced epithelioid sarcoma of adrenal gland: A case report","volume":"24","author":"Wang","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13569-016-0064-0","article-title":"Response to anti-PD1 therapy with nivolumab in metastatic sarcomas","volume":"6","author":"Paoluzzi","year":"2016","journal-title":"Clin. Sarcoma Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"Mahoney","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/CJI.0000000000000332","article-title":"Rapid and complete response to combination anti-CTLA-4 and anti-PD-1 check point inhibitor therapy in a patient with stage IV refractory end-stage epithelioid sarcoma: A case report","volume":"43","author":"Pecora","year":"2020","journal-title":"J. Immunother."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Gong, T.J., Tang, F., Zheng, C.X., Wang, J., Wang, Y.T., Zhang, Y.H., Luo, Y., Zhou, Y., Min, L., and Tu, C.Q. (2021). Case report: Pulmonary metastases from epithelioid sarcoma in extremity favourably responding to immunotherapy with camrelizumab. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.728437"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3892\/ol.2013.1247","article-title":"Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report","volume":"5","author":"Ratnavelu","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: A single-centre single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e001561","DOI":"10.1136\/jitc-2020-001561","article-title":"Nivolumab and sunitinib combination in advanced soft tissue sarcomas: A multicenter, single-arm, phase Ib\/II trial","volume":"8","author":"Hindi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1158\/1078-0432.CCR-16-2349","article-title":"Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: A phase Ib study of dasatinib plus ipilimumab","volume":"23","author":"Shoushtari","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Noujaim, J., Thway, K., Bajwa, Z., Bajwa, A., Maki, R.G., Jones, R.L., and Keller, C. (2015). Epithelioid sarcoma: Opportunities for biology-driven targeted therapy. Front. Oncol., 5.","DOI":"10.3389\/fonc.2015.00186"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Stacchiotti, S., Zuco, V., Tortoreto, M., Cominetti, D., Frezza, A.M., Percio, S., Indio, V., Barisella, M., Monti, V., and Brich, S. (2019). Comparative assessment of antitumor effects and autophagy induction as a resistance mechanism by cytotoxics and EZH2 inhibition in INI1-negative epithelioid sarcoma patient-derived xenograft. Cancers, 11.","DOI":"10.3390\/cancers11071015"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Berlow, N.E., Rikhi, R., Geltzeiler, M., Abraham, J., Svalina, M.N., Davis, L.E., Wise, E., Mancini, M., Noujaim, J., and Mansoor, A. (2019). Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5681-6"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbrc.2022.07.052","article-title":"Establishment of an epithelioid sarcoma PDCs and PDX to evaluate drug sensitivity","volume":"625","author":"Wang","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Wakamatsu, T., Ogawa, H., Yoshida, K., Matsuoka, Y., Shizuma, K., Imura, Y., Tamiya, H., Nakai, S., Yagi, T., and Nagata, S. (2022). Establishment of organoids from human epithelioid sarcoma with the air-liquid interface organoid cultures. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.893592"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2717\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:47:20Z","timestamp":1787312840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":141,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162717"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162717","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}